Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 17/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 17/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 17/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 15/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6197406 | 0.87 | GABRA1 (0.53) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6202954 | 0.87 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6199182 | 0.86 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6202126 | 0.85 | GABRA1 (0.58) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6200691 | 0.84 | GABRA1 (0.61) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6200896 | 0.83 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6201408 | 0.83 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6202421 | 0.82 | GABRG2 (0.60) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6201582 | 0.82 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6200541 | 0.82 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343788-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-23 | — | — | EP | claimed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | claimed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | claimed |
| EP-1343788-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | disclosed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | GABRA2, GABRA5, GABRA1 | GABRA1 3/4885GABRG2 14/4885GABRB3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.